MustangBio
    • About
      • About Mustang Bio
      • Leadership
      • Board of Directors
      • In the News
      • Contact
    • Our Approach
      • Our Approach
      • About CAR T Cell Therapy
      • Publications
    • Pipeline
      • Pipeline
      • Clinical Trials
    • Partnering
      • Partnering
      • Active Collaborations
    • Careers
    • Investor Relations
      • News & Events
      • Company Info
      • Financial Info
      • Stock Data
      • SEC Filings
      • Governance

    Press Releases

    Investors

    Investors

    • Overview
    • News & Events
      • Overview
      • Press Releases
      • IR Calendar
      • Email Alerts
    • Company Info
      • Overview
      • Management Team
      • Presentations
      • Contacts
      • FAQ
    • Financial Info
      • Overview
      • Financial Results
      • Income Statement
      • Balance Sheet
      • Cash Flow
    • Stock Data
      • Quote
      • Charts
      • Historical Data
    • SEC Filings
      • Overview
      • All SEC Filings
      • Annual Reports
      • Quarterly Reports
      • Section 16 Filings
    • Governance
      • Overview
      • Board of Directors
      • Board Committees
      • Governance Documents
    • News & Events

    • Overview
    • Press Releases
    • IR Calendar
    • Email Alerts
    June 16, 2021

    Mustang Bio to Present at the Raymond James Human Health Innovation Conference

    June 11, 2021

    Mustang Bio Announces Updated Interim Phase 1/2 Data for MB-106 CD20-Targeted CAR T in Patients with Relapsed or Refractory B-cell Non-Hodgkin Lymphomas and Chronic Lymphocytic Leukemia

    June 7, 2021

    Mustang Bio to Host Key Opinion Leader Webinar on MB-106 CD20-Targeted CAR T for the Treatment of High-Risk B-Cell Non-Hodgkin Lymphomas and Chronic Lymphocytic Leukemia

    May 18, 2021

    Mustang Bio and City of Hope Announce First Patient Dosed in Phase 1 Clinical Trial of MB-101 (IL13Rα2-specific CAR T cells) to Treat Leptomeningeal Brain Tumors

    May 14, 2021

    Mustang Bio Reports First Quarter 2021 Financial Results and Recent Corporate Highlights

    May 12, 2021

    Mustang Bio Announces MB-106 CD20-Targeted CAR T Data Selected for Presentation at European Hematology Association 2021 Virtual Congress

    May 10, 2021

    Mustang Bio Announces FDA Acceptance of IND Application for MB-106, a CD20-Targeted CAR T Therapy

    April 21, 2021

    Mustang Bio to Participate in Chardan’s 5th Annual Genetic Medicines Manufacturing Summit

    March 24, 2021

    Mustang Bio Reports Full-Year 2020 Financial Results and Recent Corporate Highlights

    March 4, 2021

    Mustang Bio to Participate in Three March 2021 Virtual Investor Conferences

    • arrow_back
    • 1
    • …
    • 4
    • 5
    • 6
    • 7
    • 8
    • 9
    • 10
    • 11
    • 12
    • 13
    • …
    • 19
    • arrow_forward
    rss_feed News RSS
    • Email Alerts
    • Contacts
    • RSS News Feed

    95 Sawyer Road, Suite 110 • Waltham, MA 02453

    781-652-4500 info@mustangbio.com

    Twitter Linkedin

    © Copyright 2025 Mustang Bio